- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | First Faculty of Medicine
- Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic2010 | Faculty of Physical Education and Sport, Faculty of Medicine in Hradec Králové
- New treatment options for psoriasis based on new findings in the pathogenesis of psoriasis - risankizumab2020 | Faculty of Medicine in Pilsen
- Imatinib (glivec) in the Treatment of patients with CML in accelerated phase and Ph+ ALL2003 | First Faculty of Medicine
- Merkel cell carcinoma - new treatment options2018 | First Faculty of Medicine
- Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy2012 | First Faculty of Medicine
- Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)2019 | Third Faculty of Medicine
- Lenalidomide treatment in myelodysplastic syndrome with 5q deletion - Czech MDS group experience2015 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
- Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study2018 | Second Faculty of Medicine
- Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1-and 2-Year Open-label Follow-up Results2015 | First Faculty of Medicine
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial2020 | First Faculty of Medicine
